|
16.03.2015 17:45:00
|
POXEL: 2015 Financial Calendar
Regulatory News:
POXEL (Paris:POXEL) (Euronext - FR0012432516), an independent French biopharmaceutical company focused on the development of antidiabetic drugs, today announces its schedule for the publication of financial information for 2015.
| Évent | Date * | ||
| 2014 Full-Year Sales | March 16, 2015 | ||
| 2014 Full-Year Financial statements | April 30, 2015 | ||
| 2015 Q1 Sales | May 5, 2015 | ||
| Annual Shareholders’ Meeting | June 16, 2015 | ||
| 2015 Q2 Sales | July 15, 2015 | ||
| 2015 June 30th, Financial statements | August 31, 2015 | ||
| 2015 Q3 Sales | October 22, 2015 | ||
| 2015 Full-Year Sales | January 28, 2016 |
* Subject to modification. Press releases are published after market closes.
About Poxel
Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Poxel SAmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Poxel SAmehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.